A clinical team wanted to design a Phase III trial for a new therapy used to treat a rare disease. To gauge economic viability, the team needed to understand how global payer organizations would weigh the benefits of the therapy and where the treatment might be placed in formularies.
A post-market advisory board helped a medical affairs team identify new opportunities for differentiation. Read the case study to learn more.
A HEOR virtual advisory board enabled a medical affairs team to develop a cost-effectiveness model. Read the success story to learn how.
One LATAM country adopted a new training standard with an asynchronous medical education program. Read the case study to learn more.